Rezolute Inc
Company Profile
Business description
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute’s pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Contact
275 Shoreline Drive
Suite 500
Redwood CityCA94065
USAT: +1 650 206-4507
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
71
Stocks News & Analysis
stocks
Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth
stocks
Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.20 | 75.80 | -0.83% |
| CAC 40 | 8,001.79 | 108.00 | -1.33% |
| DAX 40 | 23,770.43 | 361.98 | -1.50% |
| Dow JONES (US) | 47,336.68 | 226.19 | -0.48% |
| FTSE 100 | 9,633.35 | 68.02 | -0.70% |
| HKSE | 25,983.52 | 174.84 | -0.67% |
| NASDAQ | 23,834.72 | 109.77 | 0.46% |
| Nikkei 225 | 51,497.20 | 914.14 | -1.74% |
| NZX 50 Index | 13,605.96 | 49.66 | 0.37% |
| S&P 500 | 6,851.97 | 11.77 | 0.17% |
| S&P/ASX 200 | 8,813.70 | 69.00 | -0.78% |
| SSE Composite Index | 3,960.19 | 16.33 | -0.41% |